TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15122749
Drug: Short-term therapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term therapy with natural IFN-alfa (6 million units) for 4 weeks, initiated 8 weeks after onset of acute hepatitis.
Study: 15122749
Drug: Short-term therapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term therapy with natural IFN-alfa (6 million units) for 4 weeks, followed by interval IFN therapy (3 times weekly for 20 weeks).
Study: 15122749
Drug: Short-term therapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term therapy with natural IFN-alfa (6 million units) for 4 weeks, initiated after 1 year of observation.
Study: 9257777
Drug: grepafloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: grepafloxacin (400 mg)
Study: 9257777
Drug: cefixime (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefixime (400 mg)
Study: 24411489
Drug: Intervention Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Formula (IF) - 1.89 g protein/100 kcal with α‐lactalbumin (ALAB) and LC‐PUFA
Study: 24411489
Drug: Control Formula
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Formula (CF) - 2.30 g protein/100 kcal with standard whey and no LC‐PUFA
Study: 18942247
Drug: Lactated ringer
Normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated ringer 20 ml/kg
Study: 18942247
Drug: 5% hypertonic
Normalized name: Walgreens Sodium Chloride 5% Hypertonicity Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% hypertonic saline 4 ml/kg followed by lactated ringer 10 ml/kg/hr
Study: 16412917
Drug: Extensive anterior
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extensive anterior capsule polishing
Study: 16412917
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (non-polishing)
Study: 8917053
Drug: Continued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment with antiepileptic drugs (AEDs)
Study: 8917053
Drug: Discontinued or
Normalized name: Entex HC Discontinued Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued or reduced treatment before the occurrence of their first seizure
Study: 8917053
Drug: Discontinued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued treatment
Study: 6287829
Drug: Pyrantel pamoate
Normalized name: Pyrantel Pamoate
DrugBank: Pyrantel (DB11156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrantel pamoate (10 mg/kg body weight daily for 2 or 3 days)
Study: 6287829
Drug: Bephenium hydroxynaphthoate
Normalized name: Bephenium hydroxynaphthoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bephenium hydroxynaphthoate (2.5 g base) and piperazine citrate (2-3 g) given daily for 2 days
Study: 30068669
Drug: Low-dose sedation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sedation (1 mg/kg propofol intravenous)
Study: 24978834
Drug: Dietary Nitrate
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary Nitrate (0.45 g)
Study: 21562143
Drug: Low-GDP bicarbonate-lactate-buffered
Normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-GDP bicarbonate-lactate-buffered PD solutions (BL)
Study: 21562143
Drug: Classic glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic glucose degradation product (GDP)-rich lactate-buffered PD solutions (L)
Study: 12607793
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily for 5 days
Study: 7647083
Drug: Yohimbine 10.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine 10.8 mg
Study: 2696020
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg iron daily
Study: 2696020
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg or 120 mg iron daily
Study: 2696020
Drug: Ferritin iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferritin iron administration
Study: 326306
Drug: Cyclandelate treatment
Normalized name: Cyclandelate
DrugBank: Cyclandelate (DB04838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclandelate treatment
Study: 30658192
Drug: Camelina sativa
Normalized name: CAMELINA SATIVA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camelina sativa oil (CSO) - 10 g of alpha-linolenic acid/day
Study: 29927180
Drug: Diltiazem +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem + ACEI/ARB (sustained-release diltiazem 120 mg daily)
Study: 24105075
Drug: EZN-2208 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZN-2208 monotherapy (9 mg/m² on days 1, 8, and 15 every 28 days for patients with KRAS-mutant tumors)
Study: 24105075
Drug: EZN-2208 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZN-2208 plus cetuximab (400 mg/m² loading dose on day 1 followed by 250 mg/m² weekly starting on day 8)
Study: 24105075
Drug: Irinotecan (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (125 mg/m² on days 1 and 8 every 21 days) plus cetuximab (400 mg/m² loading dose on day 1 followed by 250 mg/m² weekly starting on day 8)
Study: 17135989
Drug: Combination Treatment
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Treatment (COMB)
Study: 14579879
Drug: Prompt L-Pop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt L-Pop self-etching adhesive plus sealant
Study: 1598875
Drug: Intravenous enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enalapril (1.25 mg) administered to group II patients after exercise testing.
Study: 6692664
Drug: Histamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine (0.5 micrograms/min) during noradrenaline infusions
Study: 6692664
Drug: Local injections
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injections of Na131I
Study: 30932165
Drug: Simultaneous GBR
Normalized name: GBR-12783
DrugBank: GBR-12783 (DB17027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous GBR with implant placement
Study: 30932165
Drug: Delayed GBR
Normalized name: GBR-12783
DrugBank: GBR-12783 (DB17027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed GBR followed by implant placement after 6 months
Study: 30231466
Drug: Walnut group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut group (28-56 g/day)
Study: 24685389
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (3 hours of therapy per day)
Study: 24685389
Drug: Continuous passive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous passive motion (CPM) device (2 hours daily throughout length of stay)
Study: 7924899
Drug: Fluconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100 mg orally
Study: 7924899
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg orally
Study: 28488192
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) at 5 mg/kg
Study: 28488192
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) at 100 mg/kg
Study: 23896011
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ibuprofen and acetaminophen
Study: 23896011
Drug: Rescue analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue analgesics
Study: 21726104
Drug: Topiramate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (200 ‐ 300 mg/day)
Study: 9469684
Drug: Sertindole, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole, a new atypical antipsychotic, details on dosage and duration not available
Study: 2656346
Drug: Azathioprine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2 mg.kg‐1.day‐1)
Study: 15250227
Drug: Conventional daytime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional daytime CPAP titration
Study: 15250227
Drug: Manual daytime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual daytime CPAP titration
Study: 15250227
Drug: Automatic daytime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic daytime CPAP titration (AutoSet)
Study: 11162417
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose inhaled beclomethasone dipropionate (BDP) 500 microg t.i.d. plus salbutamol 200 microg t.i.d.
Study: 2544132
Drug: Digoxin (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (continued treatment)
Study: 1098764
Drug: Oral testolactone
Normalized name: Testolactone
DrugBank: Testolactone (DB00894)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral testolactone
Study: 1098764
Drug: Intravenous fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fluorouracil alone
Study: 1098764
Drug: Combined androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined androgen and antimetabolite therapy
Study: 27028002
Drug: Resistant dextrin
Normalized name: wheat dextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant dextrin (10 g daily for 8 weeks)
Study: 24075361
Drug: 40% dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% dextrose gel 200 mg/kg
Study: 21807139
Drug: Water-based therapy
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-based therapy
Study: 21807139
Drug: Land-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Land-based therapy (active control group)
Study: 16418664
Drug: Mersilene mesh‐wrapped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mersilene mesh‐wrapped hydroxyapatite (MHA) orbital implant
Study: 16418664
Drug: Sclera‐wrapped hydroxyapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclera‐wrapped hydroxyapatite (SHA) orbital implant
Study: 9404904
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg bid)
Study: 3327149
Drug: b.i.d. (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: b.i.d. (2 x 500 mg)
Study: 3327149
Drug: q.i.d. (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: q.i.d. (4 x 250 mg)
Study: 24552468
Drug: LED group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED group (7 patients) - Evaluation of biochemical markers (IL-1β, TGF-β, PGE2, NO) in peri-implant crevicular fluid (PICF).
Study: 17690595
Drug: Escitalopram (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (mean maximally tolerated dose: 25.0 mg, standard deviation=8.4)
Study: 11756067
Drug: Raw green
Normalized name: raw sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw green banana flour (RBF) 30 g/d
Study: 11756067
Drug: Cooked green
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooked green banana flour (CBF) 30 g/d
Study: 11756067
Drug: Plant-polysaccharide-free diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant-polysaccharide-free diet with RBF 30 g/d
Study: 2683905
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (AB) 50 mg twice daily
Study: 28542874
Drug: Ixekizumab (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab (160 mg starting dose, then 80 mg every 2 weeks for 12 weeks, then 80 mg every 4 weeks)
Study: 28542874
Drug: Ustekinumab (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (45 mg or 90 mg weight-based dosing)
Study: 25145882
Drug: Shoe inserts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shoe inserts and daily plantar-specific stretching
Study: 19230959
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (88 microg twice daily)
Study: 15350853
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT; n = 26)
Study: 8726925
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg 16 h nicotine patches (LC‐15)
Study: 8726925
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg 16 h nicotine patches (HC‐25)
Study: 8726925
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg 16 h nicotine patches (HC‐15)
Study: 6124653
Drug: Beta‐1‐adrenergic blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta‐1‐adrenergic blockade (100 mg metoprolol)
Study: 17631786
Drug: Topical adelmidrol
Normalized name: Adelmidrol
DrugBank: Adelmidrol (DB16083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical adelmidrol 2% emulsion applied twice daily
Study: 17631786
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (6 patches in 6 subjects with multiple lesions that had not been treated)
Study: 11836291
Drug: Leuprolide 3‐month
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide 3‐month depot 22.5 mg im every 12 wk for 48 wk
Study: 10761536
Drug: Combination regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimen of mefloquine (750 mg) and quinine (600 mg)
Study: 10761536
Drug: Quinine sulfate
Normalized name: Quinine Sulfate
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine sulfate (600 mg)
Study: 10761536
Drug: Mefloquine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (750 mg) alone
Study: 31028165
Drug: 18F‐PSMA‐11 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F‐PSMA‐11 administered at 2 MBq per kilogram of body weight
Study: 28504321
Drug: 0.25% intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% intranasal phenylephrine (Group 2)
Study: 28504321
Drug: 0.5% intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% intranasal phenylephrine (Group 3)
Study: 28504321
Drug: Intranasal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline (Group 1)
Study: 25343233
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) 1000 mg infusions, two doses 2 weeks apart
Study: 25343233
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline infusions), two doses 2 weeks apart
Study: 24652170
Drug: Iron amino
Normalized name: Iron amino acid chelate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron amino acid chelate (12.5 mg of iron in 13 g of milk)
Study: 24652170
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (12.5 mg of iron in 13 g of milk)
Study: 9237960
Drug: 18 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g/d olestra
Study: 9237960
Drug: 18 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g/d olestra plus 1.1 mg tocopheryl acetate/g olestra
Study: 9237960
Drug: Placebo (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (18 g/d triglyceride)
Study: 8513842
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg codeine
Study: 8513842
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg codeine
Study: 2880688
Drug: Fenoldopam (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam (doses greater than 0.25 microgram/kg/min)
Study: 31650711
Drug: Vixotrigine 150
Normalized name: Vixotrigine
DrugBank: Vixotrigine (DB11706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vixotrigine 150 mg 3 times a day (days 16-28) with carbamazepine 100 mg twice a day (days 1-3) and 200 mg twice a day (days 4-21)
Study: 31650711
Drug: Vixotrigine 150
Normalized name: Vixotrigine
DrugBank: Vixotrigine (DB11706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vixotrigine 150 mg 3 times a day (days 16-28) after carbamazepine discontinuation
Study: 31609706
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (Group A)
Study: 31609706
Drug: High creatinine
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High creatinine levels (>0.6 mg/dl)
Study: 28678950
Drug: 1% sodium
Normalized name: Dextrose 5% and 0.11% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% sodium alendronate (ALN) gel
Study: 25733460
Drug: Dairy products
Normalized name: Food - Dairy Products, Whey, Cow's Milk
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy products (474 mL/d 2% milk and 170 g/d low-fat yogurt)
Study: 25733460
Drug: Sugar-sweetened products
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-sweetened products (710 mL/d nondiet soda and 108 g/d nondairy pudding)
Study: 21258823
Drug: Multimodal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal therapy including cognitive-behavioral therapy
Study: 19592602
Drug: Conventional cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cigarette (CC, tar: 11 mg, Nic: 0.8 mg)
Study: 19592602
Drug: Electrically Heated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrically Heated Cigarette Smoking System (EHCSS: tar: 5 mg, Nic: 0.3 mg)
Study: 16415300
Drug: IIb/IIIa inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIb/IIIa inhibitors with GuardWire embolic protection
Study: 16415300
Drug: IIb/IIIa inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIb/IIIa inhibitors with FilterWire embolic protection
Study: 16415300
Drug: FilterWire embolic
Normalized name: HOSE ANTI-EMBOLISM CALF LEN LARGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: FilterWire embolic protection without IIb/IIIa inhibitors
Study: 16415300
Drug: IIb/IIIa inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIb/IIIa inhibitors
Study: 14728071
Drug: Losartan 50‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50‐100 mg/day
Study: 14728071
Drug: Atenolol 50‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50‐100 mg/day
Study: 1492270
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of drug cream (papaverine and phentolamine)
Study: 22846159
Drug: memantine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: memantine (titrated up by 5 mg week⁻¹ to 20 mg)
Study: 11535316
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine, administered orally with childhood vaccines at 2, 4, and 6 months of age
Study: 11535316
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine
Study: 9692077
Drug: Intermittent monofluorophosphate
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent monofluorophosphate 114 mg/day plus continuous calcium supplementation (950-1000 mg/day)
Study: 9692077
Drug: Continuous calcium
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous calcium (1000 mg/day) alone
Study: 7848337
Drug: Theophyllard (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophyllard (test preparation)
Study: 2525943
Drug: Etodolac (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac (300 mg, twice daily)
Study: 2525943
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg, twice daily)
Study: 30097133
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) treatment and clinical monitoring
Study: 20610947
Drug: Drug use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug use among street children
Study: 16801296
Drug: Nicotine spray
Normalized name: nicotine Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine spray (active)
Study: 1466325
Drug: nicardipine-SR 45
Normalized name: nicardipine hydrochloride 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nicardipine-SR 45 mg twice daily
Study: 1466325
Drug: nicardipine-SR 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: nicardipine-SR 60 mg twice daily
Study: 1466325
Drug: verapamil-SR 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil-SR 240 mg once daily
Study: 29538220
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine warm compress (CMWC)
Study: 29538220
Drug: WHO 3-step
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO 3-step analgesic ladder treatment
Study: 30640989
Drug: Conventional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional care plus intermittent limb pressure treatment
Study: 30640989
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intermittent limb pressure treatment)
Study: 24668714
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg) added to 30 ml 0.25% levobupivacaine
Study: 24668714
Drug: Levobupivacaine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (30 ml 0.25%) with 2 ml 0.9% NaCl
Study: 23415776
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (fortified cefazolin sodium 5% and tobramycin sulfate 1.3%)
Study: 23415776
Drug: Monotherapy (moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (moxifloxacin 0.5%)
Study: 15818702
Drug: Naproxen 1000
Normalized name: naproxen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 1000 mg